1[1]Blum JL,Jones SE,Fay JW,et al.Guideline for systenic therapy of early stage breast cance[J].Breast Cancer Res Treat 1997,43:259～276
2[2]Early Breast Cancer Trialists Collbaborative GrouP.Polychemotherapy for early breast cancer:An overview of the randomized trials[J].Lancet,1998,352:930～942.
3[3]Eifel P,Axelson JA,Costa J,et al.National instirutes of Health Consensus Development Conrerence Statement:A djuvant therapy for breast cancer[J].J Natl CancerInst,2001,93:979～989.
4[4]Launchbuty AP,Habboubi N.Epirubicin and doxorubicin:A comparison of the characteristics therapeutic activity and toxicity[J].Cancer Treat Rev,1993,18:197～228.
5[5]Fisher B Anderson S,Decillis A,et al.Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer:findings from National Surgical A djuvant Breast and Bowel projest B-25 [J].J Clin Oncol.1999,17:3347～3388.
6[6]Hortobagyi GN,Buzdar U,Theriault RL,et al.Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma[J].J Nat1 Inst,2000,92:225～233.
7[7]Piccart MJ,Goldhirsch A,Gelber RD.Controversies in adjuvant systemic therapy of breast cancer:introduction.In:Perry MC,American Society of Clinical Oncology 2002 Educational Book[M].Alexandria:Lippincott Willians & Wilkins,2002.138～143.
8[8]Nabholtz JM,Pienkowski T,mackey ,et al.Phase trial comparing TAC(docetaxel,doxorubicin,cyclophosphamide)with FAC(5-fluorouracial ,doxorubicin,cyclophosphamide)in the adjuvant treatment of node positive breast cancer(BC)patients:interim analysis of the BCIRG 001 study[M].Proceedings of ASCO 2002Alexandria:LIppincott Willians Wilkins,2002.36a:141.
9[9]Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J].J Clin Oncol,1998,16;2672～2685.
10[10]Mamounas Ep.Overview of National Surgical Adjuvant Breast and Bowel project neoadjuvant chemotherapy studies[J].Semin Oncol,1998,Suppl 3(25):31～35.
9Jones S,Erban J,Overmoyer B,et al.Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast caneer[c].The 26th Annual SanAntoino Breast Cancer Symposium,2003,10.
10Maiche A G,Jekunen A P,Kaleva-Kerola J,et al.High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated pastients with advanced breast carcinoma[J],Cancer,2000,88(8):1863～1868.
